Building a Leader in Biotech
In anticipation of its initial public offering (IPO), clinical-stage biotech company Apellis Pharmaceuticals asked Denterlein to develop and execute a comprehensive, fully-integrated communications strategy designed to raise awareness of the company and its development of novel therapeutic compounds to treat rare diseases, such as Geographic Atrophy and PNH.
key business, trade, and regional/local press
Average quarter over quarter growth in social media followers across Twitter and LinkedIn
Unique social media engagements across the company's Twitter
Establishing a Position in the Marketplace
Our team devised and implemented a communications program based on strategic positioning and messaging, producing a steady cadence of "on the record" news, securing executive/leadership visibility opportunities, and launching and managing Apellis’ social media channels.
“The work we do daily with clients on the leading edge of developing life changing technologies and innovations in healthcare is truly rewarding.”